Research
Research
Anderson KE, Sahu M, DiStefano MJ, Asche C, Mattingly II TJ. Pharmacy Closures and Anticonvulsant Medication Prescription Fills. Journal of the American Medical Association (JAMA). 2024; Online ahead of print.
Liu A, Anderson KE, Levy J, Johnson TV, Polsky D, Anderson G. Changes in macular degeneration physician-administered drug prescribing after implementation of step therapy in Medicare Advantage. JAMA Health Forum. 2024; 5(8): e242446.
Anderson KE, Chaiyakunapruk N, Gutierrez EJ, Schmutz HW, Rose MR, Brixner D, McQueen RB. State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization. Health Affairs. 2024; 43(8): 1137-1146.
Xu JF, Anderson KE, Liu A, Polsky D. Medicare Advantage Plan Characteristics Associated with Sorting their Beneficiaries to Providers that Generate Fewer Avoidable Hospital Stays. Health Services Research. 2024; 59(4): e14335.
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola N, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. PharmacoEconomics. 2024; 42(3): 319-328.
Anderson KE, Wu RJ, Darden M, Jain A. Medicare Advantage Is Associated with Lower Utilization of Total Joint Arthroplasty. The Journal of Bone and Joint Surgery. 2024; 106(3): 198.
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare Drug Price Negotiation Program. Expert Review of Pharmacoeconomics & Outcomes Research. 2024; 24(2): 171-180.
Nicholas LH, Polsky D, Darden M, Xu J, Anderson K, Meyers DJ. Is There An Advantage? Considerations for Researchers Studying the Effects of the Type of Medicare Coverage. Health Services Research. 2024; 59(1): e14264.
Liu A, Xuan A, Socal M, Anderson G, Anderson KE. Filgrastim and Infliximab Biosimilar Uptake in Medicare Advantage Compared to Traditional Medicare, 2016-2019. Journal of Managed Care and Specialty Pharmacy. 2024; 30(1): 15-21.
Xu J, Anderson KE, Liu A, Miller BJ, Polsky D. Role of Patient Sorting in Avoidable Hospital Stays in Medicare Advantage vs Traditional Medicare. JAMA Health Forum. 2023; 4(11): e233931.
Anderson KE, DiStefano MJ [co-first authors], Liu A, Mattingly TJ, Socal M, Anderson GF. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing into Medicare Payment for Expensive Part B Drugs. Value in Health. 2023; 26(9): 1381-1388.
Anderson KE, Xuan A, Anderson G, Socal M. Estimating Changes in Medicare Part D and Commercial Insurer Spending for Insulin with the Introduction of State-Led Biosimilar Insulins in California. JAMA Internal Medicine. 2023; 183(7): 734-735.
McQueen RB, Anderson KE, Levy JF, Carlson JJ. Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable? PharmacoEconomics. 2023; 41(3): 321-327.
Anderson KE, Darden M, Jain A. Improving Prior Authorization in Medicare Advantage. Journal of the American Medical Association (JAMA). 2022; 328(15): 1497-1498.
Nguyen AM, Anderson KE, Anderson G, Johnson TV. The Association between Open Payments-reported Industry Transfers of Value and Prostaglandin Analog Prescribing. JAMA Ophthalmology. 2022; 140(9): 855-862.
Topazian RJ, McGinty EE, Han H, Levine AS, Anderson KE, Presskreischer R, Barry CL. Americans’ Beliefs about Harassing or Threatening Public Health Officials During the COVID-19 Pandemic. JAMA Network Open. 2022; 5(7): e2223491.
Anderson KE, Alexander GC, Ma C, Dy SM, Sen AP. Medicare Advantage Coverage Restrictions for the Costliest Physician-Administered Drugs. American Journal of Managed Care. 2022; 28(7): e255-e262.
Anderson KE, Polsky D, Dy S, Sen AP. Prescribing of Low versus High-Cost Part B Drugs in Medicare Advantage and Traditional Medicare. Health Services Research. 2022; 57(3): 537-547.
Presskreischer R, Steinglass JE, Anderson KE. Eating Disorders in the U.S. Medicare Population. International Journal of Eating Disorders. 2022; 55(3):362-371.
Hussaini SMQ, Gupta A, Anderson KE, Ballreich JM, Nicholas LH, Alexander GC. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. JAMA Network Open. 2022; 5(3): e221117.
Sen AP, Meiselbach M, Anderson KE, Miller B, Polsky D. Physician Network Breadth and Plan Quality Ratings in Medicare Advantage. JAMA Health Forum. 2021; 2(7): e211816.
Anderson KE, Shugarman LR, Davenport K. Regulation of Provider Networks in Response to COVID-19. American Journal of Managed Care. 2021; 27(4): e101-e104.
Anderson KE, Alexander GC, Niles L, Scholle SH, Saloner B, Dy SM. Quality of Preventive and Chronic Illness Care for Insured Adults with Opioid Use Disorder. JAMA Network Open. 2021; 4(4): e214925.
Anderson KE, Saloner B, Eckstein J, Chaisson CE, Scholle SH, Niles L, Dy S, Alexander GC. Quality of Buprenorphine Care for Insured Adults with Opioid Use Disorder. Medical Care. 2021; 59(5): 393-401.
Barry CL, Anderson KE, Han H, Presskreischer R, McGinty EE. Change Over Time in Public Support for Social Distancing, Mask Wearing, and Contact Tracing to Combat the COVID-19 Pandemic. American Journal of Public Health. 2021; 111(5): 937-948.
Anderson KE, McGinty EE, Presskreischer R, Barry CL. Reports of Forgone Medical Care Among US Adults During the Initial Phase of the COVID-19 Pandemic. JAMA Network Open. 2021; 4(1): e2034882.
McGinty EE, Presskreischer R, Anderson KE, Han H, Barry CL. Psychological Distress and COVID-19 Related Stressors Reported in a Longitudinal Cohort of U.S. Adults in April and July 2020. Journal of the American Medical Association (JAMA). 2020; 324(24): 2555-2557.
Hambley BC, Anderson KE [co-first authors], Shanbhag SP, Sen AP, Anderson GF. Payment Incentives and the Use of Higher-Cost Drugs: A Retrospective Cohort Analysis of Intravenous Iron in the Medicare Population. American Journal of Managed Care. 2020; 26(12): 516-522.
Barry CL, Han H, Presskreischer R, Anderson KE, McGinty EE. Public Support for Social Safety-Net Policies for Covid-19 in the US, April 2020. American Journal of Public Health. 2020; 110(12): 1811-1813.
MacDonnell-Yilmaz RE, Anderson KE, DeNardo B, Sprinz P, Padula WV. Cost-effectiveness Analysis of Screening Extremely Low Birthweight Children for Hepatoblastoma Using Serum Alpha-fetoprotein. The Journal of Pediatrics. 2020; 225: 80-9.
Socal MP, Anderson KE, Sen A, Bai G, Anderson GF. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim. Value in Health. 2020; 23(4): 481-486.
Jain A, Levy J, Polsky D, Anderson K. Medicare Advantage and the Maryland All-Payer Model. Health Affairs Forefront. March 18, 2022.
Sen AP, Parasrampuria S, Anderson KE, Anderson G. Catastrophic Coverage in the Medicare Part D Drug Benefit: Which Beneficiaries Need It and How Much Are They Spending? Issue Brief. Commonwealth Foundation. September 2020.
Ballreich J, Alexander GC, Anderson G, Anderson K, et al. Pharmaceuticals: Innovation, Access, and Affordability Chartbook. A Report from the Johns Hopkins Drug Access and Affordability Initiative. 2019.